 BetterLife Pharma Inc., a biotech company focused on the development of cutting-edge treatments for mental disorders, revealed that it has obtained its first set of neurological receptor binding data on its lead compound, 2-bromo-LSD TD-0148A. The Vancouver-based company said the data was generated by Eurofins Discovery. 